Browse by Track

PII-001 - POPULATION PHARMACOKINETICS OF TRASTUZUMAB REZETECAN IN PATIENTS WITH HER2 EXPRESSING OR MUTATED ADVANCED MALIGNANT SOLID TUMORS

PI-003 - BIOMARKER UTILIZATION IN NEUROLOGICAL DRUG PRODUCTS APPROVED BY FDA (2008-2023): A LANDSCAPE ANALYSIS.

PI-004 - DIGITAL HEALTH BIOMARKERS FOR CHARACTERIZING DEPRESSION SEVERITY TRAJECTORIES DURING ANTIDEPRESSANT TREATMENT.

PI-007 - PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.

PI-008 - USING BIOMARKERS TO PROVIDE EVIDENCE OF EFFECTIVENESS IN DRUG DEVELOPMENT FOR RARE DISEASES: SURVEY RESULTS FOR APPROVED ENZYME REPLACEMENT THERAPIES.

PII-003 - COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.

PII-004 - EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES

PII-005 - ITPA ACTIVITY TO PREDICT REMISSION WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS

PII-006 - PHARMACODYNAMIC MODELS AS EARLY PREDICTORS OF WEIGHT LOSS EFFICACY IN EARLY-PHASE CLINICAL RESEARCH

PII-007 - PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS

LB-001 - MODELING AND SIMULATION OF POLYAMINE KINETICS DURING ACUTE KIDNEY INJURY

PT-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.

OAII-002 - EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA

PWII-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.

PII-008 - MICRORNA REGULATING SEL1L INVOLVED IN THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS EXPRESSION LEVELS IN PATIENT PLASMA.

PI-009 - ASSESSMENT OF KNOWLEDGE AND PERCEPTION OF CAR-T CELL THERAPY AMONG HEALTHCARE PROVIDERS IN SAUDI ARABIA

PI-010 - LIMITED SAMPLING STRATEGIES FOR NONCOMPARTMENTAL ANALYSES OF ENCORAFENIB PHARMACOKINETIC DATA

PII-009 - EVALUATION OF ANTIBIOTIC TREATMENTS FOR CELLULITIS: A SYSTEMATIC REVIEW FROM CLINICALTRIALS.GOV

PII-010 - PHYSICIAN PERCEPTIONS ON ORAL HEALTH FOR PREGNANT WOMEN: BANGLADESH PERSPECTIVE

PI-011 - ABSORPTION OF ELIGLUSTAT VIA THE BUCCAL CAVITY FOLLOWING ORAL ADMINISTRATION OF ELIGLUSTAT SOLUTION IN HEALTHY ADULT PARTICIPANTS.

PI-012 - CONCENTRATION-QT ANALYSIS FOR BAY 2927088 INDICATES NO CLINICALLY RELEVANT QTC INTERVAL PROLONGATION

PI-013 - CONSIDERATIONS ON HUMAN ADME STUDIES AND PROPOSED DECISION TREE TOWARDS TAILORED STUDY DESIGNS.

PI-014 - RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV-103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO-DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS.

PII-011 - CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.

PII-012 - CONSIDERATIONS FOR PHASE 1 CLINICAL TRIALS IN ADULT PATIENTS

PII-013 - EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS

PII-014 - SAFETY , TOLERABILITY, AND PHARMACOKINETICS OF SM17 IN HEALTHY VOLUNTEERS, A NOVEL IL-17 RECEPTOR B TARGETING ANTIBODY IN PHASE I DEVELOPMENT FOR THE TREATMENT OF ASTHMA

LB-003 - EXPLORING Δ-9-TETRAHYDROCANNABINOL (THC) INDUCED “FEELING HIGH” USING A PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL

PI-015 - IMPACT OF RIFAMPICIN DOSE ON LINEZOLID PHARMACOKINETICS IN TUBERCULOUS MENINGITIS: INSIGHTS FROM THE ALTER TRIAL

PI-016 - SELTOREXANT DOES NOT PROLONG THE QT INTERVAL: A PLACEBO- AND POSITIVE-CONTROLLED, SINGLE DOSE PHASE 1 STUDY IN HEALTHY ADULTS

PII-015 - MODELING AND SIMULATION ANALYSIS TO SUPPORT DOSE SELECTION FOR MAM01, A NOVEL ANTI-CIRCUMSPOROZOITE PROTEIN MONOCLONAL ANTIBODY, IN UPCOMING TRIALS

PI-017 - CONCENTRATION-RESPONSE RELATIONSHIP OF MAM01, AN INVESTIGATIONAL MONOCLONAL ANTIBODY TARGETING THE CIRCUMSPOROZOITE PROTEIN (CSP), IN A CONTROLLED HUMAN INFECTION MODEL (CHIM) STUDY.

PI-020 - PREDICTING OPTIMAL PATIENT-CENTRIC TREATMENT DURATION FOR LEVOFLOXACIN-CONTAINING TUBERCULOSIS REGIMEN: AN INTEGRATED APPROACH OF A MODEL-BASED STRATIFICATION TOOL WITH SITE-OF-DISEASE PHARMACOLOGY KNOWLEDGE

PI-021 - THE EFFECTS OF OPIOIDS ON BLOOD-BRAIN BARRIER INTEGRITY, ANTIRETROVIRAL ACCUMULATION, AND NEUROINFLAMMATORY CHEMOKINE PROFILES IN ECOHIV-INFECTED MICE

PII-018 - INTESTINAL MICROBIOME AND METABOLOME FLUCTUATIONS IN PATIENTS RECEIVING INTENSE CHEMOTHERAPY FOR AML: RESULTS FROM A PILOT, PROSPECTIVE OBSERVATIONAL STUDY

PII-019 - POPULATION PHARMACOKINETICS OF DELAMANID AND ITS METABOLITE DM-6705 IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS RECEIVING NOVEL SHORT-COURSE ORAL REGIMENS IN THE ENDTB AND ENDTB-Q TRIALS

PII-020 - SIMILAR BIOAVAILABILITY OF SUBCUTANEOUS BEPIROVIRSEN WHEN DELIVERED FROM A VIAL OR PREFILLED SYRINGE FITTED WITH A SAFETY SYRINGE DEVICE IN HEALTHY ADULT PARTICIPANTS

PII-021 - VIRAL VANGUARD: TURNING THE TIDE AGAINST SUPERBUGS

PI-023 - INCORPORATING HEPATIC TRANSPORTER ZONATION INTO PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS: IMPLICATIONS FOR PRAVASTATIN DISPOSITION IN WHITE AND CHINESE POPULATIONS CONSIDERING OATP1B1 PHENOTYPES.

PT-004 - INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.

PII-022 - CLINICAL DRUG-DRUG INTERACTION STUDIES INVESTIGATING THE EFFECT OF BAY 2927088 ON P-GP AND BCRP USING DABIGATRAN ETEXILATE AND ROSUVASTATIN

PII-023 - PBPK MODEL DEVELOPMENT AND VALIDATION FOR ROSUVASTATIN: INTEGRATING IN VITRO, CLINICAL PHARMACOKINETIC, AND LIVER PET IMAGING DATA TO IMPROVE PREDICTIONS OF OATP1B- AND BCRP-MEDIATED DRUG-DRUG INTERACTIONS

E-002 - REDUCTION IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OBSERVED WITH DORAVIRINE (DOR) IS CAUSED BY INHIBITION OF ORGANIC CATION TRANSPORTER 2 (OCT2)

PWII-003 - INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.

PI-025 - PATIENT PROFILES OF OPIOID USE DISORDER PATIENTS TREATED WITH ORAL VERSUS MONTHLY INJECTABLE BUPRENORPHINE USING U.S. REAL-WORLD MEDICAID CLAIMS DATA.

PII-024 - CHARACTERIZING METHADONE:METABOLITE RATIO DURING METHADONE INDUCTION IN PREGNANCY

PII-025 - THE POTENTIAL OF SMARTWATCH-DERIVED CARDIAC MEASUREMENTS AS BIOMARKERS OF THERAPEUTIC RESPONSE IN CHILDREN WITH DISRUPTIVE BEHAVIOR DISORDER

PI-026 - A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS

PT-006 - PHARMACOKINETIC DRUG-DRUG INTERACTION POTENTIAL OF ORAL ANTICANCER DRUGS.

PII-026 - AN INTEGRATED PK/PD MODELING FRAMEWORK OF NONCLINICAL EFFICACY AND CLINICAL HEMATOLOGICAL SAFETY TO INFORM DOSE SELECTION OF ATRI TUVUSERTIB IN COMBINATION WITH NIRAPARIB IN PATIENTS WITH PARPI-RESISTANT OVARIAN CANCER

PII-027 - CHARACTERIZING NETUPITANT'S FUNCTION AS AN NADK2 INHIBITOR: IMPACT ON CELL VIABILITY AND METABOLISM.

PII-028 - CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER

PII-031 - INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS

PII-032 - MOVING TOWARD "FIT-FOR-PURPOSE" QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING IN DRUG DEVELOPMENT: CASE EXAMPLES IN ONCOLOGY.

PII-033 - NO EFFECT OF IMMUNOGENICITY ON THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF THE NOVEL OLIGONUCLEOTIDE TELOMERASE INHIBITOR IMETELSTAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

PII-034 - OPTIMIZING DOSE SELECTION FOR CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY IN THE TREATMENT OF PATIENTS WITH CANCER : A SYSTEMATIC REVIEW OF MECHANISTIC IN SILICO MODELS.

PII-035 - PHARMACOKINETICS OF AMG 193 (A SMALL MOLECULE MTA-COOPERATIVE PRMT5 INHIBITOR) AFTER SINGLE AND MULTIPLE DOSING IN THE FASTED AND FED IN STATE PATIENTS WITH MTAP DELETED TUMORS

PII-036 - PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS

PII-037 - REAL-WORLD CHARACTERIZATION OF DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS

PII-038 - STRATEGIC CONSIDERATIONS FOR TUMOR DYNAMICS MODELING IN EARLY DEVELOPMENT: LEARNINGS FROM AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE

PII-039 - THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER IN HEALTHY ADULTS.

PII-040 - THE IMPACT OF MILD, MODERATE AND SEVERE LIVER DYSFUNCTION ON THE PHARMACOKINETIC DISPOSITION OF MEZIGDOMIDE

LB-005 - TALAZOPARIB FORMULATION BRIDGING IN CANCER PATIENTS-CHALLENGES AND THE CRITICAL ROLE OF MIDD IN APPROVAL DESPITE FAILED BIOEQUIVALENCE

PI-027 - ASSESSING BASELINE AND LONGITUDINAL CIRCULATING TUMOR DNA WITH PROGRESSION FREE SURVIVAL (PFS) IN BRAF V600E MUTANT (BRAFM) METASTATIC COLORECTAL CANCER (MCRC).

PI-028 - CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS

PI-033 - MULTISTATE MODEL TO INVESTIGATE OVERALL SURVIVAL (OS) FROM COPANLISIB PIVOTAL TRIALS.

PI-034 - ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK

PI-035 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)

PI-036 - POPULATION PHARMACOKINETIC MODELING OF SUNITINIB AND SU12662 IN PATIENTS WITH SOLID TUMORS

OAI-004 - GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.

PI-042 - AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.

PI-044 - DISRUPTING THE PD-L1 AND PDS5B INTERACTION BY COMPOUNDS: A PROMISING THERAPEUTIC STRATEGY FOR TRIPLE-NEGATIVE BREAST CANCER.

PI-046 - GENOME WIDE ASSOCIATION STUDY OF APPARENT TREATMENT RESISTANT HYPERTENSION (ATRH): INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM.

PT-007 - EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION

PT-009 - SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS

PT-010 - YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS

PII-041 - A CASE OF HEPATOTOXICITY DURING COMBINATION AXITINIB AND PEMBROLIZUMAB THERAPY IN A CYP3A4 AND CYP3A5 DUAL POOR METABOLIZER

PII-043 - ASSOCIATION BETWEEN CYP2D6 GENOTYPE-INHIBITOR INTERACTIONS AND PAIN-RELATED EMERGENCY DEPARTMENT VISITS IN CYP2D6-OPIOID-TREATED PATIENTS

PII-047 - GENOME-WIDE ASSOCIATION STUDY IDENTIFIES ASSOCIATIONS WITH METHOTREXATE RESPONSE IN PULMONARY SARCOIDOSIS.

PII-049 - IDENTIFYING FUNCTIONAL REGULATORY SNPS THAT REGULATE CYP2C9 EXPRESSION TO OPTIMIZE CYP2C9 BIOMARKER PANELS.

PII-050 - IMPACT OF SOCIAL DETERMINANTS OF HEALTH COMPOSITE MEASURES ON OUTCOMES AFTER PCI IN P2Y12 INHIBITOR-TREATED PATIENTS

PII-051 - METHYLATION PROFILING AND PATHWAY ENRICHMENT ANALYSIS REVEAL EPIGENETIC MECHANISMS IN CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS .

LB-006 - CLINICAL AND ETHICAL PERSPECTIVES ON THE EMERGING ROLE OF PHARMACOGENOMIC TESTING AMONG MENTAL HEALTH PROVIDERS: A QUALITATIVE EXAMINATION

OAI-001 - YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS

OAI-002 - EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION

OAI-003 - REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.

PWI-002 - SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS

PI-057 - AN INVESTIGATION INTO THE DOSE-DEPENDENT FOOD-EFFECT FOR DRUGS.

PI-059 - CASDATIFAN (AB521) PHARMACOKINETICS IS SIMILAR WHEN ADMINISTERED AS CAPSULES OR TABLETS AND IS UNAFFECTED BY FOOD

PI-062 - CONCENTRATION-QTC ANALYSIS OF PATRITUMAB DERUXTECAN IN PATIENTS WITH HER3-EXPRESSING METASTATIC BREAST CANCER OR METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

PI-065 - EFFECT OF FOOD AND ESOMEPRAZOLE ON THE PHARMACOKINETICS (PK) OF BAY 2927088

PI-066 - EXPLORATORY POPULATION PHARMACOKINETICS AND WEIGHT LOSS MODELING OF HRS9531, A NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST IN CHINESE OBESE ADULTS

PI-067 - EXPOSURE-EFFICACY ANALYSIS OF CAMRELIZUMAB PLUS RIVOCERANIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.

PI-068 - EXPOSURE-RESPONSE ANALYSIS OF MK-5475 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

PI-069 - FIRST IN HUMAN POPULATION PHARMACOKINETIC ANALYSIS OF THE EGFR INHIBITOR WSD0922-FU.

PI-071 - LEVERAGING AGENTIC WORKFLOWS FOR PK/PD ANALYSIS: ENHANCING CLINICAL PHARMACOLOGY DECISION-MAKING

PI-074 - MODEL-BASED DRUG DEVELOPMENT CONSIDERATIONS: ZANIDATAMAB IN PATIENTS WITH HER2 EXPRESSING BILIARY TRACT CANCER (BTC)

PI-076 - PATIENT-CENTRIC MICROSAMPLING VERSUS TRADITIONAL BLOOD SAMPLING: A PHARMACOKINETIC STUDY OF ZAVEGEPANT

PI-077 - PHARMACOKINETIC ANALYSIS OF SEVASEMTEN IN A PHASE 1 STUDY IN HEALTHY SUBJECTS AND BECKER MUSCULAR DYSTROPHY PATIENTS

PI-078 - PHARMACOKINETIC INTERACTION STUDIES OF COADMINISTRATION OF TAZEMETOSTAT WITH FLUCONAZOLE, REPAGLINIDE, OR OMEPRAZOLE IN PATIENTS WITH ADVANCED MALIGNANCIES.

PI-079 - PHARMACOKINETICS OF EDG-7500, A FIRST-IN-CLASS CARDIAC SARCOMERE MODULATOR FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

PI-081 - PHARMACOMETRIC MACHINE LEARNING: INTEGRATING NEURAL NETWORKS FOR FLEXIBLE, ADVANCED COVARIATE ANALYSIS

PI-083 - POPULATION PHARMACOKINETIC ANALYSIS OF DUVAKITUG (TEV-48574) IN HEALTHY PARTICIPANTS AND PATIENTS WITH ASTHMA.

PI-084 - POPULATION PHARMACOKINETIC ANALYSIS OF SOTATERCEPT IN JAPANESE HEALTHY PARTICIPANTS AND JAPANESE PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION.

PI-087 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR NTLA-2002 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

PI-089 - POPULATION PHARMACOKINETICS OF PYRAZINAMIDE FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS

PI-092 - THE SUPER APPROACH AS AN ALTERNATIVE FOR ESTIMATING THE PKPD PARAMETERS OF DRUGS IN COMBINATION THERAPIES

PT-011 - DEVELOPING A SIMULTANEOUS PLASMA AND CENTRAL NERVOUS SYSTEM POPULATION PHARMACOKINETIC MODEL FOR DOLUTEGRAVIR EXPOSURE

PT-012 - FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.

PT-013 - USING MODEL-BASED SIMULATIONS TO ALIGN MOUSE ANTIBIOTIC EXPOSURE WITH HUMAN CLINICAL EFFICACY FOR EXPLORATION OF COMBINATION THERAPY IN TUBERCULOSIS

PII-054 - A PHASE 1, OPEN-LABEL STUDY IN HEALTHY MALE SUBJECTS OF THE ABSORPTION, METABOLISM, EXCRETION, AND PHARMACOKINETICS OF SEVASEMTEN

PII-055 - A RANDOMIZED, THREE-PERIOD, CROSSOVER STUDY OF SINGLE AND REPEATED DOSES OF ELIGLUSTAT IN HEALTHY PARTICIPANTS, CYP2D6 EXTENSIVE AND POOR METABOLIZERS

PII-057 - AN AUTOMATED COMPARISON PLATFORM FOR INFORMED DRUG LABELING DECISIONS: WEIGHT-BASED DOSING VS. WEIGHT-BANDED DOSING.

PII-058 - APPROACHES TO HANDLING MISSING DOSING IN POPULATION PHARMACOKINETIC MODELING DUE TO NON-ADHERENCE

PII-059 - ASSESSMET OF SUBCUTANEOUS SITE OF INJECTION ON THE PK OF SOTATERCEPT

PII-061 - CLINICAL DRUG-DRUG INTERACTION STUDIES THROUGH CYTOCHROME P450 3A (CYP3A) AND P-GLYCOPROTEIN (P-GP) FOR BAY 2927088 USING ITRACONAZOLE (ITZ), CARBAMAZEPINE (CBZ) AND MIDAZOLAM (MDZ)

PII-064 - DRUG-DRUG INTERACTION MODEL DESCRIBES HIGH-DOSE METHOTREXATE PHARMACOKINETICS AFTER GLUCARPIDASE RESCUE

PII-067 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE-2 TO HIGH-RISK MYELOFIBROSIS WITH OR WITHOUT PRIOR RUXOLITNIB EXPOSURE.

PII-068 - EXPOSURE-RESPONSE ANALYSES FOR EFFICACY AND SAFETY OF BMS-986365, A DUAL ANDROGEN RECEPTOR LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

PII-069 - EXTERNAL EVALUATION OF A POPULATION PHARMACOKINETICS MODEL OF CRITICALLY ILL PEDIATRIC PATIENTS RECEIVING MEROPENEM

PII-070 - FIRST-IN-PEDIATRIC DOSE SELECTION OF PATRITUMAB DERUXTECAN USING MODELING AND SIMULATION

PII-075 - MODEL-BASED EVALUATION OF DELANDISTROGENE MOXEPARVOVEC ADENO-ASSOCIATED VIRUS PHARMACOKINETICS AND SAFETY IMPLICATIONS

PII-081 - PHARMACOKINETICS OF THB001, AN ORALLY AVAILABLE, POTENT AND HIGHLY SELECTIVE SMALL MOLECULE INHIBITOR OF WILD TYPE KIT RECEPTOR TYROSINE KINASE, IN HEALTHY VOLUNTEERS

PII-082 - POPULATION EXPOSURE-RESPONSE ANALYSIS OF INOTUZUMAB OZOGAMICIN EFFICACY AND SAFETY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.

PII-083 - POPULATION PHARMACOKINETIC (POPPK) MODELING OF ENCORAFENIB (ENCO) IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS IN PHASE 1, 2, AND 3 STUDIES: A SEMIMECHANISTIC AUTOINDUCTION MODEL.

PII-084 - POPULATION PHARMACOKINETIC ANALYSIS OF MK-5475 IN HEALTHY PARTICIPANTS AND PATIENTS WITH PULMONARY HYPERTENSION

PII-085 - POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSIS OF ABATACEPT IN COVID-19 PATIENTS

PII-086 - POPULATION PHARMACOKINETIC MODELING OF FAMITINIB IN PATIENTS WITH VARIOUS CANCER TYPES INCLUDING METASTATIC CERVICAL CANCER

PII-088 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR THE BIFUNCTIONAL PD-L1/TGF-βRII FUSION PROTEIN RETLIRAFUSP ALPHA TO SUPPORT A FLAT DOSE AS AN ALTERNATIVE REGIMEN

PII-091 - SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF IN-115314, A NOVEL SELECTIVE JAK1 INHIBITOR, AFTER A SINGLE OR MULTIPLE ORAL ADMINISTRATION IN HEALTHY MALE PARTICIPANTS.

LB-010 - A PHARMACOLOGY AND PHYSIOLOGY ENABLED MACHINE LEARNING MODEL FOR PHARMACOKINETICS OF ANTIBODY-BASED THERAPEUTICS

LB-011 - BIIB091, A NONCOVALENT BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF MULTILE SCLEROSIS (MS): MASS BALANCE, ELIMINATION ROUTE, AND METABOLISM IN HEALTHY MALE PARTICIPANTS.

LB-012 - EVALUATION OF THE EFFECT OF CYP3A4 AND P-GLYCOPROTEIN INHIBITION BY ITRACONAZOLE OR INDUCTION BY RIFAMPICIN ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES

LB-013 - PHARMACOKINETIC EVALUATION OF A NATURAL HEMP EXTRACT-BASED COSMETIC PRODUCT AFTER TOPICAL AND ORAL ADMINISTRATIONS.

LB-015 - POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN PATIENTS WITH ADVANCED CANCER.

LB-016 - QUANTIFYING HEART RATE CHANGES AFTER Δ-9-TETRAHYDROCANNABINOL (THC) ADMINISTRATION USING A PBPK-PD MODEL IN HEALTHY ADULTS

PWI-005 - FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.

PI-097 - MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS

PI-098 - PBPK MODEL REPRODUCIBILITY: LEARNINGS FROM THE DEVELOPMENT OF A PBPK MODEL REPOSITORY FOR GLOBAL HEALTH

PI-101 - PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION

PI-102 - PREDICTION OF A CLAUDIN 18.2 TARGETED ANTIBODY DRUG CONJUGATE (ADC) PHARMACOKINETICS IN CANCER PATIENTS USING PBPK MODELING AND SIMULATION

PI-103 - UTILISING PHYSIOLOGICAL LYMPH FLOWS TO ENHANCE A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC AND QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR BIODISTRIBUTION OF MRNA ENCAPSULATED IN LIPID NANOPARTICLES WITH LIPID 5 IN RATS

PII-095 - ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.

PII-096 - DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO PREDICT PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS FOR REPOTRECTINIB

PII-097 - MECHANISTIC INSIGHTS INTO CYTOKINE ANTAGONIST-DRUG INTERACTIONS: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH WITH TOCILIZUMAB AS A CASE STUDY

PII-098 - ON TRANSLATING PHYSIOLOGICALLY BASED PHARMACOKINETICS INTO CLINICAL CARE: REAL-WORLD PREDICTABILITY OF VALPROATE THERAPEUTIC DRUG MONITORING.

PII-099 - PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS

PII-100 - PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTING DRUG-DRUG INTERACTIONS (DDI) OF SHR2554

PII-104 - UTILIZING A MINIMAL PBPK (MPBPK) MODEL TO PREDICT INTRA-TUMORAL CONCENTRATIONS OF MONOCLONAL ANTIBODIES.

E-003 - A QUANTITATIVE SYSTEMS PHARMACOLOGY QSP) MODEL FRAMEWORK FOR COMBINED CLINICAL EFFICACY AND HEMATOLOGICAL TOXICITY PRECITIONS FOR ANTIBODY DRUG CONJUGATES.

E-004 - DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER

LB-017 - ASSESSING THE IMPACT OF AGE ON CANNABINOID DISPOSITION

LB-019 - CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?

LB-020 - DEVELOPMENT OF AN R SHINY APPLICATION TO STREAMLINE DRUG-DRUG INTERACTION SIMULATIONS UTILIZING THE SIMCYP-R PACKAGE.

PWI-003 - ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT

PWII-002 - DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT

PI-104 - BARRIERS AND FACILITATORS IN BRINGING MODEL-INFORMED PRECISION DOSING TO THE PATIENT'S BEDSIDE: A SYSTEMATIC REVIEW

PII-105 - EFFECT OF P-GLYCOPROTEIN INHIBITION ON TWO TACROLIMUS FORMULATIONS: A RANDOMIZED, 4-SEQUENCE, CROSS-OVER, DRUG-DRUG INTERACTION STUDY

PT-018 - AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY

E-006 - CXCR4 ANTAGONISM CORRECTS PERIPHERAL NEUTROPENIA IN A MOUSE MODEL OF WHIM SYNDROME.

PII-106 - POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS

OAII-001 - AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY

PT-019 - APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS

LB-022 - CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.

PI-109 - IMPACT OF RISK EVALUATION AND MITIGATION STRATEGY PROGRAMS ON PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT

PII-107 - CLINICAL STUDY TO INVESTIGATE THE EFFECT OF ADMINISTRATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND AN OPIOID ON VENTILATION.

OAII-003 - APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS

PWII-005 - CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS

PI-110 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE

PI-114 - POPULATION PHARMACOKINETIC ANALYSIS TO OPTIMIZE THE DOSING REGIMEN OF 17-OHPC FOR PREVENTION OF PRETERM BIRTH

PI-115 - THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTIC (MPRINT) KNOWLEDGEBASE PORTAL: A POWERFUL INFRASTRUCTURE FOR MATERNAL AND PEDIATRIC PRECISION THERAPEUTICS RESEARCH

PII-110 - AN OVERVIEW OF FOOD EFFECT STUDIES IN PEDIATRIC POPULATION SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) (2004-2024)

PII-111 - ESTABLISHING EVIDENCE-BASED, ANTENATAL DOSE RECOMMENDATIONS FOR AMOXICILLIN (WITH AND WITHOUT CLAVULANIC ACID)

PII-114 - RELATIVE IMPACT OF CYP2D6 GENOTYPE PHENOTYPE ON EXPOSURE OF SSRIS DURING PREGNANCY: EXTRAPOLATION APPROACH USING RWD AND PBPK MODELLING

PWI-004 - IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.

PT-023 - DEVELOPMENT OF AN ADVANCED PBPK MODEL OF THE RESPIRATORY TRACT TO OPTIMIZE PULMONARY DELIVERY AND DOSING OF MO-OH-NAP TROPOLONE NANO-FORMULATION.

PT-025 - EVALUATION OF PYRAZINAMIDE PHARMACOKINETICS IN ADOLESCENTS AND ADULTS TO INFORM TUBERCULOSIS DOSING RECOMMENDATIONS.

PI-116 - APPRAISAL OF PHARMACODYNAMIC CLAMP STUDY DESIGN FOR GLP-1 RECEPTOR AGONISTS.

PI-117 - DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL AND R-SHINY SIMULATION PLATFORM FOR MOXIFLOXACIN IN NON-HUMAN PRIMATES

PI-119 - EUGLYCEMIC CLAMP STUDY DESIGNS FOR NOVEL INSULINS AND INSULIN BIOSIMILARS.

PII-120 - MARFAN: MAXIMIZING ATENOLOL RESPONSE THROUGH FUNCTIONAL ASSESSMENT INVESITGATIONS AMONGST CONNECTIVE TISSUE DISORDERS

PWI-001 - DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT

OAII-004 - UTILIZING ADAPTIVE DOSING SIMULATIONS AND MACHINE LEARNING TO IMPROVE PREDICTION AND MANAGEMENT OF NEUTROPENIA RATES.

PI-123 - A MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK FOR MODEL-INFORMED TRANSLATIONAL ASSESSMENT OF MESENCHYMAL STEM CELL THERAPY IN LUPUS NEPHRITIS

PI-124 - AN INTEGRATED ANALYSIS OF FOUR TARGETED THORIUM CONJUGATES TO ASSESS THE TH-227 AND RA-223 DISTRIBUTION AND TISSUE-RELATED RADIATION.

PI-125 - QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF LONCASTUXIMAB TESIRINE-LPYL COMBINED WITH T CELL-DEPENDENT BISPECIFIC ANTIBODIES BRIDGES KNOWLEDGE AND DOSE REGIMEN STRATEGY FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

PII-123 - A STUDY ON THE PREVALENCE OF CHRONIC CANNABINOID USE INDUCING HYPEREMESIS SYNDROME

PII-124 - PREDICTION OF CLINICAL OUTCOMES IN A HETEROGENOUS NSCLC VIRTUAL PATIENT POPULATION: A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.

PII-125 - QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING BIOLOGXSYM AND MECHANISTIC TOXICITY DATA FROM A BIOMIMETIC LIVER MICROPHYSIOLOGY SYSTEM PREDICTS BIOLOGICS-INDUCED LIVER INJURY (BILI) FOR MULTIPLE LARGE MOLECULES.

PWII-004 - MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH

PI-126 - APPLICATION OF MACHINE LEARNING TO GUIDE OPTIMAL FORMULATION SELECTION IN EARLY-STAGE DRUG DISCOVERY

PI-127 - EFFECT OF HYPERTENSION (HTN) AND BLOOD PRESSURE (BP) CONTROL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.

PII-126 - DEVELOPMENT OF A SKIN DRYNESS PREDICTION MODEL BASED ON FACIAL IMAGES USING DEEP LEARNING: A PROSPECTIVE COHORT STUDY.